Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNT-101 in healthy, overweight, and obese adults
NCT07307274Phase 1Completed
- Sponsor
- Syntis Bio
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Polymer-based Nanoparticles, Device-based Delivery, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Active Drug SYNT101 with Placebo (2 arms). Primary endpoint: Safety Evaluation at 36 days. Started Jan 2026; status: completed.
02
Drugs
SYNT-101
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07307274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307274.